In the past we have often heard about shortages of products containing the active ingredient Epinephrine; also known as Adrenaline. But taking a closer look at it one could always identify the real cause. It was either a manufacturer withdrawing their pharmaceutical formulation from the market or a supply chain issues related to medical device needed for injecting the finished dosage.
 
Transo-Pharm´s robust supply chain and our 2-year safety stock have always and will always ensures the availability of Epinephrine, dispelling supply shortage fears.

Dear Customers,
 
On May 25th we informed you about the fire accident at our Contract Manufacturer Syn-Tech in Taiwan.
 
We are happy to inform you that the next production campaign for Epinephrine and Epinephrine bitartrate started – only 3 weeks after the incident.
 
Thanks to the Syn-Tech colleagues for this tremendeous effort and excellent support during these difficult weeks.
 
Needless to say, there are no delays in deliveries as we are still supplying the API’s from our stock in Hamburg/Germany.

Dear Customers,
 
We regret to inform you that Syn-Tech Chem. & Pharm., Co Ltd. had a fire accident on May 20, 2021. Fortunately, nobody of the employees or the firefighters were injured.
 
The production facility where Epinephrine and Epinephrine bitartrate are produced are not affected at all.
​The same applies to raw & starting material warehouse, finished product warehouse and QA/QC labs. Nevertheless, a detailed review and investigation is currently underway.
 
Due to our extensive stockpiling program at our German site, Transo-Pharm can easely compensate such an event and can continue the supply of both API’s according to the existing demands and forecasts.
 
Please be assured that we continuously keep you updated on the status at our partner in Taiwan.

Enantiomeric purity in chiral molecules – such as Transo-Pharm’ s Epinephrine Base and Bitartrate – have been in the focus of the health authorities for some time now. Transo-Pharm is well prepared to fully satisfy the more stringent requirements with their state-of-the-art stereo-selective manufacturing process. Transo-Pharm is therefore in the position to achieve an Enantiomeric Excess (ee) of 99% in commercial production for several years now. This is a significant contribution to ensure patient safety.

Please find the full article below. Learn more about the science behind this topic.